Wooree Bio Reports Q1 2026 Operating Loss, Debt Ratio at 226.5%
Consolidated Q1 2026 (Jan-Mar) revenue of 269.2 billion won (-9.8% YoY), operating loss of 4.3 billion won (vs operating profit of 0.8 billion in Q1 2025).
Net profit attributable to parent of 2.2 billion won (vs net loss of 9.4 billion in full year 2025), driven by non-operating gains including FX gains of 16.8 billion and derivative gains of 1.7 billion.
Debt ratio rose to 226.5% from 191.5% at end of 2025; total borrowings of 123.0 billion won; cash and cash equivalents increased to 141.3 billion from 107.0 billion.
Cash dividend of 20 won per share (total approx. 0.94 billion won) for FY2025 approved at March 2026 AGM and paid in April 2026.
Holds 1,249,200 treasury shares (2.6%); 550,000 shares reserved for employee RSU compensation, remainder to be canceled.
Net foreign currency assets of 71.5 billion won; a 5% change in exchange rates would impact pre-tax profit by 3.6 billion won.
Key segments: LED/BLU (95.2% of sales), Bio (4.8%); Bio segment recorded operating loss of 5.0 billion won.
March 2026 AGM approved amendments to articles of incorporation to reflect revised Commercial Act (independent director ratio, audit committee composition).